Pharmaxis Builds Senior Management Team
February 16 2009 - 7:04PM
PR Newswire (US)
SYDNEY, Feb. 16 /PRNewswire-Asia/ -- Pharmaceutical company
Pharmaxis (ASX:PXS)(NASDAQ:PXSL) today announced that it had
appointed Dr Howard Fox to its senior management team in the
position of Chief Medical Officer. Dr Fox will assume
responsibility for regulatory affairs, pharmacovigilance and
medical affairs. Clinical Operations will continue to report to the
Medical Director, Dr Brett Charlton. Dr Fox has more than 15 years
experience in the international pharmaceutical industry, the last
ten of which has been in respiratory product development. He was
most recently with Novartis as a Global Brand Medical Director and
previously held the positions of Senior Clinical Research Physician
and Principle Medical Expert for Novartis. Dr Alan Robertson,
Pharmaxis Chief Executive Officer said: "The appointment of Howard
Fox provides the international regulatory and pharmacovigilance
experience necessary for Pharmaxis to bring Bronchitol successfully
and rapidly to the market and we are very much looking forward to
his contribution." Dr Fox who has just relocated from the United
Kingdom will be based at the company's head office in Sydney. About
Pharmaxis Pharmaxis (ACN 082 811 630) is a specialist
pharmaceutical company involved in the research, development and
commercialization of therapeutic products for chronic respiratory
and immune disorders. Its development pipeline of products includes
Aridol for the management of asthma, Bronchitol for cystic
fibrosis, bronchiectasis and chronic obstructive pulmonary disease
(COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for
asthma. Founded in 1998, Pharmaxis is listed on the Australian
Securities Exchange (symbol PXS), and on NASDAQ Global Market
(symbol PXSL). The company is headquartered in Sydney at its
TGA-approved manufacturing facilities. For more information about
Pharmaxis, go to http://www.pharmaxis.com.au/ or contact Investor
Relations on phone +61 2 9454 7200. Forward-Looking Statements The
statements contained in this media release that are not purely
historical are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements in this media release include statements
regarding our expectations, beliefs, hopes, goals, intentions,
initiatives or strategies, including statements regarding the
potential for Aridol and/or Bronchitol. All forward-looking
statements included in this media release are based upon
information available to us as of the date hereof, and we assume no
obligation to update any such forward-looking statement as a result
of new information, future events or otherwise. We cannot guarantee
that any product candidate will receive FDA or other regulatory
approval or that we will seek any such approval. Factors that could
cause or contribute to such differences include, but are not
limited to, factors discussed in the "Risk Factors and Other
Uncertainties" section of our Form 20-F lodged with the U.S.
Securities and Exchange Commission. For more information, please
contact: Alan Robertson, Chief Executive Officer Tel:
+61-2-9454-7200 Email: RELEASED THROUGH: Australia: Felicity
Moffatt, Tel: +61-418-677-701 Email: United States: Brandon Lewis,
Trout Group, Tel: +1-646-378-2915 Email: DATASOURCE: Pharmaxis Ltd.
CONTACT: Alan Robertson, Chief Executive Officer, +61-2-9454-7200,
or ; or RELEASED THROUGH: Australia: Felicity Moffatt,
+61-418-677-701, or ; or United States: Brandon Lewis of Trout
Group, +1-646-378-2915, or Web site: http://www.pharmaxis.com.au/
Copyright
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ:PXSL)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Pharmaxis Limited - Sponsored Adr (Australia) (MM) (NASDAQ): 0 recent articles
More Pharmaxis Limited - Sponsored Adr (Australia) (MM) News Articles